Compare
Haemonetics Corp vs Merit Medical Systems Inc vs Integra Lifesciences Holdings Corp vs Embecta Corp.
| Latest fiscal year | Haemonetics Corp HAE | Merit Medical Systems Inc MMSI | Integra Lifesciences Holdings Corp IART | Embecta Corp. EMBC |
|---|---|---|---|---|
| Year ended | 2026-03-28 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $1.33B | $1.52B | $1.64B | $1.08B |
| Revenue growth (YoY) | -2.0% | +11.8% | +1.5% | -3.8% |
| Gross margin | 59.0% | 48.7% | 50.9% (computed) | 62.6% |
| Operating margin | 11.7% | 12.2% | -30.2% | 22.4% |
| Net margin | 7.3% | 8.5% | -31.6% | 8.8% |
| Net income | $97.31M | $128.49M | -$516.47M | $95.40M |
| EPS (Diluted) | $2.05 | $2.13 | -$6.74 | $1.62 |
| Operating cash flow | $293.22M | $297.37M | $50.38M | $191.70M |
| Free cash flow | $260.44M | $215.66M | -$31.05M | $182.40M |
| Cash & equivalents | $245.44M | $446.40M | $235.05M | $225.50M |
| Total assets | $2.40B | $2.69B | $3.60B | $1.09B |
| Total liabilities | n/a | $1.10B | $2.56B | n/a |
| Shareholders' equity | $796.32M | $1.58B | $1.04B | -$650.60M |
| Return on year-end equity | 12.2% | 8.1% | -49.5% | n/a |
| Shares outstanding | 45.25M | 59.42M | n/a | 58.50M |
Revenue, most recent five fiscal years
| Fiscal year | Haemonetics Corp | Merit Medical Systems Inc | Integra Lifesciences Holdings Corp | Embecta Corp. |
|---|---|---|---|---|
| Latest | $1.33B Ended 2026-03-28 | $1.52B Ended 2025-12-31 | $1.64B Ended 2025-12-31 | $1.08B Ended 2025-09-30 |
| 1 year earlier | $1.36B Ended 2025-03-29 | $1.36B Ended 2024-12-31 | $1.61B Ended 2024-12-31 | $1.12B Ended 2024-09-30 |
| 2 years earlier | $1.31B Ended 2024-03-30 | $1.26B Ended 2023-12-31 | $1.54B Ended 2023-12-31 | $1.12B Ended 2023-09-30 |
| 3 years earlier | $1.17B Ended 2023-04-01 | $1.15B Ended 2022-12-31 | $1.56B Ended 2022-12-31 | $1.13B Ended 2022-09-30 |
| 4 years earlier | $993.20M Ended 2022-04-02 | $1.07B Ended 2021-12-31 | $1.54B Ended 2021-12-31 | $1.17B Ended 2021-09-30 |